Identification | Back Directory | [Name]
(S)-3-BOC-AMINO-2-PIPERIDONE | [CAS]
92235-39-7 | [Synonyms]
N-Boc L-Orinithine LactaM 3-Pyridinol,8-(aminomethyl)- (S)-3-BOC-AMINO-2-PIPERIDONE (S)-3-Boc-aminopiperidin-2-one (S)-3-(Boc-amino)-2-oxopiperidine (3S)-2-Oxo-3-(Boc-amino)piperidine t-Butyl (S)-2-oxopiperidin-3-ylcarbamate 3-tert-butyloxycarbonylamino-2-piperidone TERT-BUTYL (S)-2-OXOPIPERIDIN-3-YLCABAMATE (S)-tert-butyl 2-oxopiperidin-3-ylcarbamate 3(S)-<(butoxycarbonyl)amino>-2-oxopiperidine N-tert-butyl-N-(2-oxopiperidin-3-yl)carbaMate tert-butyl [(3S)-2-oxopiperidin-3-yl]carbaMate tert-butyl N-[(3S)-2-oxopiperidin-3-yl]carbaMate N-[(3S)-2-Oxo-3-piperidinyl]carbamic Acid tert-Butyl E
ster N-[(3S)-2-Oxo-3-piperidinyl]carbamic Acid tert-Butyl E
ster,99%e.e. Carbamic acid, N-[(3S)-2-oxo-3-piperidinyl]-, 1,1-dimethylethyl ester | [Molecular Formula]
C10H18N2O3 | [MDL Number]
MFCD08166304 | [MOL File]
92235-39-7.mol | [Molecular Weight]
214.26 |
Chemical Properties | Back Directory | [Melting point ]
203-205 °C | [Boiling point ]
405.6±34.0 °C(Predicted) | [density ]
1.11±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [pka]
11.05±0.20(Predicted) | [Appearance]
White to off-white Solid | [Optical Rotation]
Consistent with structure |
Hazard Information | Back Directory | [Uses]
N-Boc L-Orinithine Lactam is used in the synthesis of Pro-Leu-Gly-NH2 analogs for dopamine receptor modulation. | [Synthesis]
General procedure for the synthesis of tert-butyl (S)-2-piperidone-3-carbamate from (S)-5-amino-2-((tert-butoxycarbonyl)amino)pentanoic acid: 64 g (2.75 mmol) of BOC-L-ORN-OH was dissolved in 275 mL of DMF at 0 °C. To this solution 1.22 g (2.75 mmol) of BOP reagent and 1.16 g (20.0 mmol) of sodium bicarbonate were added. The reaction mixture was stirred at room temperature for 12 hours. Upon completion of the reaction, the mixture was concentrated under reduced pressure to about 5 mL. The concentrated mixture was diluted with 100 mL of water and saturated sodium bicarbonate solution (1:1) and subsequently extracted with three 100 mL portions of ethyl acetate (EtOAc). The organic phases were combined, washed sequentially with 300 mL of water and 300 mL of brine, dried over anhydrous sodium sulfate (Na2SO4), filtered, and concentrated under reduced pressure to afford the target product (S)-tert-butyl (S)-piperidin-2-one-3-carbamate (133) as a colorless solid in 0.37 g (62%) yield. The product was analyzed by silica gel thin layer chromatography (TLC) with an Rf value of 0.55 (unfolding agent: dichloromethane-methanol = 10:1). Nuclear magnetic resonance hydrogen spectra (1H NMR, CDCl3) showed δ 1.32 (s, 9H), 1.45-1.64 (m, 1H), 1.65-1.84 (m, 2H), 2.10-2.30 (m, 1H), 3.15-3.25 (m, 2H), 3.79-4.05 (m, 1H), 5.62 (br s, 1H) and 6.99 (br s, 1H). Nuclear magnetic resonance carbon spectra (13C NMR, CDCl3) showed δ 27.7, 28.2, 36.56, 36.61, 41.5, 51.0, 79.5, 156.0 and 172.3. | [References]
[1] Journal of Medicinal Chemistry, 1996, vol. 39, # 23, p. 4531 - 4536 [2] Patent: WO2016/118877, 2016, A1. Location in patent: Paragraph 00208 |
|
|